KR101274543B1 - 인간 아드레날린 β３ 수용체 리간드, 이를 포함하는 식품 및 의약품 - Google Patents

인간 아드레날린 β３ 수용체 리간드, 이를 포함하는 식품 및 의약품 Download PDF

Info

Publication number
KR101274543B1
KR101274543B1 KR1020117000640A KR20117000640A KR101274543B1 KR 101274543 B1 KR101274543 B1 KR 101274543B1 KR 1020117000640 A KR1020117000640 A KR 1020117000640A KR 20117000640 A KR20117000640 A KR 20117000640A KR 101274543 B1 KR101274543 B1 KR 101274543B1
Authority
KR
South Korea
Prior art keywords
acid
component
fat
cells
unsaturated fatty
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020117000640A
Other languages
English (en)
Korean (ko)
Other versions
KR20110017437A (ko
Inventor
야수오 푸지모토
쇼이치 구리하라
타다오 하마야
Original Assignee
리콤 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 리콤 코포레이션 filed Critical 리콤 코포레이션
Publication of KR20110017437A publication Critical patent/KR20110017437A/ko
Application granted granted Critical
Publication of KR101274543B1 publication Critical patent/KR101274543B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
KR1020117000640A 2008-06-11 2009-06-11 인간 아드레날린 β３ 수용체 리간드, 이를 포함하는 식품 및 의약품 Expired - Fee Related KR101274543B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JPJP-P-2008-153390 2008-06-11
JP2008153390 2008-06-11
PCT/JP2009/060682 WO2009151094A1 (ja) 2008-06-11 2009-06-11 ヒトアドレナリンβ3受容体リガンド、これを含む食品及び医薬品

Publications (2)

Publication Number Publication Date
KR20110017437A KR20110017437A (ko) 2011-02-21
KR101274543B1 true KR101274543B1 (ko) 2013-06-17

Family

ID=41416798

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020117000640A Expired - Fee Related KR101274543B1 (ko) 2008-06-11 2009-06-11 인간 아드레날린 β３ 수용체 리간드, 이를 포함하는 식품 및 의약품

Country Status (7)

Country Link
US (1) US20110098358A1 (enExample)
EP (1) EP2316445A4 (enExample)
JP (2) JP5544660B2 (enExample)
KR (1) KR101274543B1 (enExample)
CN (1) CN102149375B (enExample)
CA (1) CA2727223C (enExample)
WO (1) WO2009151094A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2922552T3 (es) * 2014-11-03 2022-09-16 Nestle Sa Métodos que utilizan la temperatura facial para evaluar el impacto posterior a la ingestión de los ingredientes alimentarios en la oxidación de grasas
US9561206B2 (en) * 2015-01-07 2017-02-07 The United States Of America, As Represented By The Secretary Of The Navy Use of heptadecanoic acid (C17:0) to detect risk of and treat hyperferritinemia and metabolic syndrome
EP3661600A4 (en) 2017-10-23 2021-08-11 Epitracker, Inc. FATTY ACID ANALOGS AND ITS USE IN THE TREATMENT OF DISEASES RELATED TO METABOLISM SYNDROME
AU2019274431B2 (en) 2018-05-23 2025-03-13 Epitracker, Inc. Compositions and methods for diagnosis and treatment of conditions related to the quality of aging and longevity
EP3908374A4 (en) 2019-01-09 2022-12-28 Epitracker, Inc. COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF NEURODEGENERATIVE DISEASES
JP7404382B2 (ja) 2019-03-04 2023-12-25 エピトラッカー インコーポレイテッド 脂肪酸アナログ、ならびに認知機能障害、行動症状および慢性疼痛の処置におけるそれらの使用
JP7500037B2 (ja) * 2019-07-24 2024-06-17 国立大学法人 東京大学 血中尿酸値低下剤及び血中尿酸値低下用食品組成物
WO2023080939A1 (en) 2021-11-03 2023-05-11 Epitracker, Inc. Pentadecanoylcarnitine for treatment of conditions related to the quality of aging and longevity

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008000440A1 (en) * 2006-06-27 2008-01-03 Lipid Nutrition B.V. Use of a polyunsaturated fatty acid compound

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2173545C (en) * 1995-04-07 2004-06-29 Kalyana Sundram Increasing the hdl level and the hdl/ldl ratio in human serum by balancing saturated and polyunsaturated dietary fatty acids
US5578334A (en) * 1995-04-07 1996-11-26 Brandeis University Increasing the HDL level and the HDL/LDL ratio in human serum with fat blends
EP1285590A1 (en) * 2001-08-08 2003-02-26 Société des Produits Nestlé S.A. Lipid blends
RU2305547C2 (ru) * 2001-08-23 2007-09-10 Вестгейт Байолоджикал Лимитед Применение апопротеинов сыворотки молока в профилактике или лечении микробной или вирусной инфекции
EP1508335B1 (en) * 2002-05-27 2011-09-28 Morinaga & Co. Ltd. Compositions comprising a cocoa fraction for use in the treatment of periodontitis caused by bacteria belonging to genus porphyromonas, prevotella, fusobacterium or actinobacillus
JP2004075653A (ja) * 2002-06-19 2004-03-11 Nisshin Oillio Ltd 体脂肪分解促進剤および飲食物
WO2004022049A1 (ja) * 2002-09-05 2004-03-18 The Nisshin Oillio Group, Ltd. 痩身剤およびその飲食物
AU2003261928A1 (en) * 2002-09-05 2004-03-29 The Nisshin Oillio Group, Ltd. Agents, foods and drinks controlling lipid metabolism
JP5102435B2 (ja) 2002-10-08 2012-12-19 株式会社リコム キトサン含有多糖、その製造方法及び用途
JP2006096666A (ja) 2002-10-31 2006-04-13 Kaneka Corp 選択的ヒトβ３アドレナリン受容体アゴニスト剤
JP2005015358A (ja) * 2003-06-25 2005-01-20 Pharma Design Inc 摂食障害の治療に供される医薬組成物
US20080146657A1 (en) * 2003-11-04 2008-06-19 Hiroshi Tsuboi Plant-Origin Alpha3-Adrenoceptor Agonist and Use of the Same
JP2005179264A (ja) * 2003-12-19 2005-07-07 Shokubutsu Kogaku Kenkyusho:Kk 体重増加抑制剤
US20060084637A1 (en) * 2004-10-18 2006-04-20 Maria Alemany Methods of using fatty-acid esters of estrogens and thermogenic compounds for reducing the body weight of a mammal and compositions containing the same
US20080200707A1 (en) * 2005-01-04 2008-08-21 Mochida-Pharmaceuticals Pharmaceutical Co., Ltd. Lipotoxicity Relieving Agent
CA2593768C (en) * 2005-01-04 2014-02-18 Mochida Pharmaceutical Co., Ltd. Use of .omega.3 unsaturated fatty acids for relieving lipotoxicity
GB0514463D0 (en) * 2005-01-31 2005-08-17 Loders Croklaan Bv Use of pinolenic acid

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008000440A1 (en) * 2006-06-27 2008-01-03 Lipid Nutrition B.V. Use of a polyunsaturated fatty acid compound

Also Published As

Publication number Publication date
CN102149375B (zh) 2015-09-30
JPWO2009151094A1 (ja) 2011-11-17
CN102149375A (zh) 2011-08-10
CA2727223C (en) 2014-10-07
EP2316445A1 (en) 2011-05-04
EP2316445A4 (en) 2011-12-21
CA2727223A1 (en) 2009-12-17
JP2014080432A (ja) 2014-05-08
JP5544660B2 (ja) 2014-07-09
US20110098358A1 (en) 2011-04-28
WO2009151094A1 (ja) 2009-12-17
KR20110017437A (ko) 2011-02-21

Similar Documents

Publication Publication Date Title
KR101274543B1 (ko) 인간 아드레날린 β３ 수용체 리간드, 이를 포함하는 식품 및 의약품
KR101809172B1 (ko) 뮤신이 없는 배지에서 배양한 아커만시아 뮤시니필라 균주 또는 이의 배양액을 유효성분으로 함유하는 대사성 질환의 예방, 개선 또는 치료용 조성물
CN103549410B (zh) 一种肠道黏膜保护与修复型肠内营养制品及其制备方法
JP6483240B2 (ja) 希少ジンセノサイドを高含量で含有する、山参もしくは高麗人参を含む高麗人参類の抽出物または高麗人参類の形成層由来植物幹細胞もしくはその抽出物の製造方法
BR112016025892B1 (pt) Lactobacillus rhamnosus mortos por calor conjugados a um aglutinante de polissacarídeo polimérico, seu método de preparação e seu uso, composição farmacêutica e composição de alimentação
WO2010021247A1 (ja) セロトニントランスポーター阻害活性を有する医薬品又は飲食品
CN103288978B (zh) 岩藻聚糖硫酸酯及其制备方法和在制备抗糖尿病的α-糖苷酶抑制剂中的应用
CN106377533A (zh) 一种海参磷脂及其在提高机体运动协调能力制品中的应用
JP2001322935A (ja) 神経細胞賦活剤およびその利用
JP2016190801A (ja) 難消化性グルカンを含有する血中中性脂肪上昇抑制剤および血中レムナント様リポ蛋白コレステロール上昇抑制剤
CN105503988A (zh) 天然抗癫痫活性化合物及其在药物制剂中的用途
WO2018012773A1 (ko) 울다비오시드 a 화합물을 함유하는 항염증 조성물
HK1157216A (en) Human b3 adrenergic receptor ligand, and food or pharmaceutical product containing the same
KR20120008366A (ko) 오미자 추출물로부터 분리된 화합물을 유효성분으로 함유하는 대장염 질환의 예방 및 치료용 조성물
JP2015021001A (ja) 納豆菌を用いたマコンブ発酵物の血圧上昇抑制剤
US20100028465A1 (en) Composition for ameliorating cerebral function
CA2966574A1 (en) Agents for maintaining undifferentiated state and promoting proliferation of stem cells
JP2016204303A (ja) 抗健忘症用組成物
JP2015193547A (ja) 運動様作用を有するレスベラトロール加熱処理組成物
KR101495607B1 (ko) Ｓ-아릴 시스테인을 유효성분으로 함유하는 비만으로 유도된 염증 치료용 조성물
EP1915142A1 (en) Composition comprising oleic acid and the use thereof
KR101785970B1 (ko) 올레산 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 근육손실 예방 및 치료용 약학적 조성물
CN1223371C (zh) 大花红景天有效成份制剂及制备方法
TWI440467B (zh) 一種可萃取牛蒡中具有減重效果之物質的方法
JP2015124151A (ja) レスベラトロール加熱処理組成物

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PE0801 Dismissal of amendment

St.27 status event code: A-2-2-P10-P12-nap-PE0801

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R17-X000 Change to representative recorded

St.27 status event code: A-5-5-R10-R17-oth-X000

FPAY Annual fee payment

Payment date: 20160602

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20170605

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

FPAY Annual fee payment

Payment date: 20190416

Year of fee payment: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20230608

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20230608